Person:
GÜNEŞ, BEGÜM

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
Organizational Unit
Job Title
Last Name
GÜNEŞ
First Name
BEGÜM
Name
Email Address
Birth Date

Search Results

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
PublicationOpen Access

Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center

2020-12-01T00:00:00Z, GÜNEŞ, BEGÜM, ONSUN, Nahide, YABACI, AYŞEGÜL, ONSUN, NAHIDE, GÜNEŞ, BEGÜM, YABACI TAK, AYŞEGÜL

There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.

Loading...
Thumbnail Image
PublicationOpen Access

Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID‐19 pandemic: The real‐world experience of a single centre

2020-12-01T00:00:00Z, Onsun, Nahide, Yabanci, Aysegul, GÜNEŞ, BEGÜM

There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long‐term drug survival data (i.e. time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR‐TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36 and 48 weeks, and annually thereafter. The behaviours of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID‐19 pandemic, were also investigated.